|
|
派安普利单抗抗肿瘤治疗的研究进展
|
Abstract:
近年来，随着恶性肿瘤发病率的不断增高，恶性肿瘤已成为全球面临的重大健康问题之一。派安普利单抗是目前世界上唯一进行Fc段改造并采用IgG1亚型的新型差异化PD-1单抗，能够有效增强免疫治疗疗效，减少不良反应，部分临床实验已经证实派安普利单抗单药或联合其他疗法治疗恶性肿瘤表现出良好的疗效及安全性。本文就派安普利单抗抗肿瘤治疗的研究进展作一简要综述。
In recent years, with the increasing incidence of malignant tumors, malignant tumors have become one of the major health problems facing the world. Penpulimab is the only new differentiated PD-1 monoclonal antibody with Fc segment modification and IgG1 subtype in the world, which can effectively enhance the efficacy of immunotherapy and reduce the adverse effects, and some clinical trials have confirmed that Penpulimab alone or in combination with other therapies for the treatment of malignant tumors has shown good efficacy and safety. In this article, we would like to briefly review the research progress on the antitumor therapy of Penpulimab.
| [1] | 2020年全球癌症统计报告[J]. 中华预防医学杂志, 2021, 55(3): 398. |
| [2] | 孙燕, 石远凯. 临床肿瘤内科手册[M]. 第5版. 北京: 人民卫生出版社, 2007: 11-21. |
| [3] | Han, C., Ye, S., Hu, C., Shen, L., Qin, Q., Bai, Y., et al. (2021) Clinical Activity and Safety of Penpulimab (Anti-PD-1) with Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Frontiers in Oncology, 11, Article 684867. https://doi.org/10.3389/fonc.2021.684867 |
| [4] | Huang, Z., Pang, X., Zhong, T., Qu, T., Chen, N., Ma, S., et al. (2022) Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, with Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Frontiers in Immunology, 13, Article 924542. https://doi.org/10.3389/fimmu.2022.924542 |
| [5] | Dagher, O.K., Schwab, R.D., Brookens, S.K. and Posey, A.D. (2023) Advances in Cancer Immunotherapies. Cell, 186, 1814-1814.E1. https://doi.org/10.1016/j.cell.2023.02.039 |
| [6] | Salmaninejad, A., Valilou, S.F., Shabgah, A.G., Aslani, S., Alimardani, M., Pasdar, A., et al. (2019) PD‐1/PD‐L1 Pathway: Basic Biology and Role in Cancer Immunotherapy. Journal of Cellular Physiology, 234, 16824-16837. https://doi.org/10.1002/jcp.28358 |
| [7] | 王思渊, 鲁辉, 杨纯. PD-1/PD-L1类单抗药物在肿瘤治疗中的应用进展[J]. 中国生物制品学杂志, 2023, 36(1): 105-111, 118. |
| [8] | 陈洪丞成, 张宏权, 魏潇凡. PD-L1表达及其调控在肿瘤治疗中作用的研究进展[J]. 生理科学进展, 2023, 54(6): 526-532. |
| [9] | Sanmamed, M.F. and Chen, L. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 175, 313-326. https://doi.org/10.1016/j.cell.2018.09.035 |
| [10] | Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L.C., Muskett, F.W., Morgan, S.H., et al. (2013) Structure and Interactions of the Human Programmed Cell Death 1 Receptor. Journal of Biological Chemistry, 288, 11771-11785. https://doi.org/10.1074/jbc.m112.448126 |
| [11] | 赵喆, 唐彦, 朱惠娟, 等. 免疫检查点抑制剂引发的免疫相关不良反应研究进展[J]. 临床药物治疗杂志, 2022, 20(6): 1-6. |
| [12] | Lei, Q., Wang, D., Sun, K., Wang, L. and Zhang, Y. (2020) Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 8, Article 672. https://doi.org/10.3389/fcell.2020.00672 |
| [13] | Morad, G., Helmink, B.A., Sharma, P. and Wargo, J.A. (2021) Hallmarks of Response, Resistance, and Toxicity to Immune Checkpoint Blockade. Cell, 184, 5309-5337. https://doi.org/10.1016/j.cell.2021.09.020 |
| [14] | Dougan, M. (2020) Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunology Research, 8, 1230-1235. https://doi.org/10.1158/2326-6066.cir-20-0372 |
| [15] | Liu, Y., Zang, X., Wang, J., Huang, S., Xu, J. and Zhang, P. (2019) Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomedicine & Pharmacotherapy, 120, Article ID: 109437. https://doi.org/10.1016/j.biopha.2019.109437 |
| [16] | Weber, J.S., Postow, M., Lao, C.D. and Schadendorf, D. (2016) Management of Adverse Events Following Treatment with Anti-Programmed Death-1 Agents. The Oncologist, 21, 1230-1240. https://doi.org/10.1634/theoncologist.2016-0055 |
| [17] | Darnell, E.P., Mooradian, M.J., Baruch, E.N., Yilmaz, M. and Reynolds, K.L. (2020) Immune-related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports, 22, Article No. 39. https://doi.org/10.1007/s11912-020-0897-9 |
| [18] | 张书培. PD-1/PD-L1抑制剂治疗所致免疫相关不良事件与晚期肿瘤患者疗效相关性研究[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2022. |
| [19] | 派安普利单抗注射液说明书[M]. 上海: 正大天晴康方(上海)生物医药科技有限公司, 2021. |
| [20] | Song, Y., Zhou, K., Jin, C., Qian, Z., Hou, M., Fan, L., et al. (2022) Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). Frontiers in Oncology, 12, Article 925236. https://doi.org/10.3389/fonc.2022.925236 |
| [21] | Zhong, H., Sun, S., Chen, J., Wang, Z., Zhao, Y., Zhang, G., et al. (2024) First-Line Penpulimab Combined with Paclitaxel and Carboplatin for Metastatic Squamous Non-Small-Cell Lung Cancer in China (AK105-302): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial. The Lancet Respiratory Medicine, 12, 355-365. https://doi.org/10.1016/s2213-2600(23)00431-9 |
